-

Catalent, Inc. to Present at the Biopharma CEO Investor Forum

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that John Chiminski, Chair and Chief Executive Officer, will virtually present at the Biopharma CEO Investor Forum at 9:45 a.m. ET on June 8, 2021.

A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.

About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), an S&P 500® Company, is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 15,000 people, including over 2,400 scientists and technicians, at more than 45 facilities across four continents, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™

Contacts

Investor Contact:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

Industry:

Catalent, Inc.

NYSE:CTLT
Release Versions
English

Contacts

Investor Contact:
Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

More News From Catalent, Inc.

Catalent and Elpida Therapeutics Enter Strategic Partnership for Late-Phase AAV Manufacturing

TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic partnership to support late-phase manufacturing of Elpida’s lead program, an AAV9 gene therapy for Spastic Paraplegia Type 50 (SPG50). Under the agreement, Catalent will also be granted exclusive manu...

Cartherics and Catalent Expand Commercial License Agreement

MELBOURNE, Australia & TAMPA, Fla.--(BUSINESS WIRE)--Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership. The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced p...

Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases

TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent and GelMEDIX Enter Global Partnership for manufacturing and development of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases...
Back to Newsroom